Its role in the AD pathology is highlighted by the fact that four of the five drugs currently approved for AD treatment are acetylcholinesterase (AChE) inhibitors, which, by preventing the breakdown of acetylcholine, increase the cholinergic tone resulting in improved cognitive outcomes, as long as sufficient cholinergic terminals persist in the telencephalon (Hampel et al., 2018; Kabir et al., 2019; Marucci et al., 2020). Here, ACHE is linked to Alzheimer disease.